Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322725 · ClinicalTrials.gov registry record
Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review
A clinical trial, sponsored by University of New Mexico.
- Terminated
- Registry status
- 25
- Enrollment target
NCT00322725: Clinical Trial study, sponsored by University of New Mexico.
NCT00322725 is a clinical trial that was terminated before completion, run by University of New Mexico. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322725 was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
1.11 Retrospectively evaluate for a correlation between tumor response and changes in systolic/diastolic/mean arterial blood pressures in patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies. 1.12 Retrospectively evaluate for differences in tumor response between patients with and without pre-existing hypertension treated with bevacizumab plus or minus chemotherapy with a wide variety of metastatic malignancies. 1.21 Determine if there were differences in bevacizumab induced hypertension rates between different tumor types. 1.22 Evaluate for differences in bevacizumab induced hypertension rates between males and females. 1.23 Examine if there were associations between a particular chemotherapeutic agent(s), that may have had an increased propensity of inducing hypertension when combined with bevacizumab.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-04 |
Why NCT00322725 stopped before completion
NCT00322725 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00322725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322725 about?
NCT00322725 is a clinical study titled "Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review". 1.11 Retrospectively evaluate for a correlation between tumor response and changes in systolic/diastolic/mean arterial blood pressures in patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies. 1.12 Retrospectively evaluate for differences in...
What is the current status of trial NCT00322725?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2006-02. Estimated completion is 2009-04.
Who is sponsoring clinical trial NCT00322725?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia